Medicine - Xagena Medicine

Medicine

News

Drugs

Xapedia

Farmaci

Farmacia

Medicina

Specialità

Interventions for impetigo, a superficial bacterial skin infection

Interferon-beta for secondary progressive multiple sclerosis

Anti-angiogenesis treatments: Bevacizumab, Sunitinib increase breast cancer stem cells

2012 - Expanded label on Berinert for self-administration and treatment of acute laryngeal attacks of hereditary angioedema, FDA approved

Eplerenone reduces atrial fibrillation in patients with mild heart failure

Selective serotonin reuptake inhibitors increase risks for elderly

Smoking-cessation drugs: Varenicline unsuitable for first-line use

Avastin for the treatment of women with newly diagnosed, advanced ovarian cancer, EU approved

Multaq linked to increased risk of death or serious cardiovascular events

Xarelto approved in the European Union for the prevention of stroke in patients with atrial fibrillation and in the treatment of deep vein thrombosis

Lantus associated with an increased risk for breast cancer

Adults with type 2 diabetes: Saxagliptin when added to Insulin maintains reductions in glycosylated hemoglobin levels over 52 weeks

No link between intracerebral hemorrhage and statin use among patients with prior stroke

Transthyretin familial amyloid polyneuropathy: Vyndaqel, first therapy approved in the European Union

Eylea injection for the treatment of wet age-related macular degeneration

Ibuprofen may lower risk of Parkinson's disease

FDA has approved Potiga to treat seizures associated with epilepsy in adults

Type 2 diabetes patients inadequately controlled with Metformin: safety and efficacy of Dapagliflozin plus Metformin at 102 weeks

Onfi as add-on therapy for seizures associated with Lennox-Gastaut syndrome, FDA approved

Sprycel linked to risk of pulmonary arterial hypertension

FDA has approved Juvisync, a fixed-dose combination of Sitagliptin and Simvastatin

FDA has approved Cialis to treat benign prostatic hyperplasia

Possible increased risk of blood clots with contraceptives containing Drospirenone

Zometa does not reduce the recurrences of breast cancer

Osteoporosis: Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min or in patients with evidence of acute renal impairment

Benefit of Ezetimibe is not proven in patients with elevated cholesterol levels

Zytiga for metastatic castration-resistant prostate cancer, approved in the European Union

Safety concerns associated with DPP-4 inhibitors

Europe: Linagliptin for treatment of diabetes mellitus type 2 approved

FDA has approved Firazyr for acute attacks of hereditary angioedema

Pegloticase for severe, chronic gout associated with improvement in symptoms

Dalcetrapib: safety profile and potential for slowing of plaque progression in patients at risk of coronary heart disease

Heart rate reduction with Ivabradine reduces clinical events in heart failure

ATOLL trial: IV Enoxaparin more effective than unfractionated Heparin in reducing PCI complications

Use of long-term, high-dose Fluconazole during pregnancy may be linked to birth defects in infants

Cubicin: risk of eosinophilic pneumonia

Multaq: risk of cardiac failure and risk of hepatotoxicity

Risk of cardiac failure when Insulin is combined with Pioglitazone

Recombinant human growth hormone: increased risk of death is inconclusive

Risk of osteonecrosis of the jaw associated with Bevacizumab and Sunitinib

Oral osteoporosis drugs: bisphosphonates and potential increased risk of esophageal cancer

Alemtuzumab reduces relapse rate by 55% compared to Interferon beta-1a in treatment-naïve multiple sclerosis patients

Anti-inflammatory drugs linked to risk of atrial fibrillation or flutter

Smoking cessation: Champix is associated with a 72% increased risk of a serious adverse cardiovascular events

Valproate: risk of impaired cognitive development in children exposed in utero

NIH stops AIM-HIGH trial on Niacin: lack of efficacy in reducing cardiovascular events

Medullary thyroid cancer: FDA has approved Vandetanib

Systemic juvenile idiopathic arthritis: FDA has approved Actemra in children ages 2 years and older

2011 - Diabetes mellitus type 2: FDA has approved Tradjenta

Duodart, a fixed dose combination medicine for benign prostatic hyperplasia

Ampyra improves walking in adults with multiple sclerosis, FDA approved

End stage renal disease: Digoxin linked to mortality

Somatropin: possible increased risk of death

Eteplirsen has demonstrated generation of greater than 50% dystrophin-positive muscle fibers in a patient following systemic administration in Duchenne muscular dystrophy

Lorcaserin causes significant weight loss and improves maintenance of weight loss

Xgeva for preventing cancer-related bone injury, FDA approved

Ticagrelor for patients with acute coronary syndromes

Mexiletine for treating symptom of muscular dystrophy

Nevirapine may be beneficial for some HIV-infected children who have achieved viral suppression

Trastuzumab-DM1 as a first-line therapy in HER2+ metastatic breast cancer

Bipolar disorder type 1: Abilify approved for maintenance treatment as an adjunct to either Lithium or Valproate ( 2011 )

FDA: Afinitor approved for subependymal giant cell astrocytoma associated with tuberous sclerosis

Postmenopausal osteoporotic women: Lasofoxifene reduces breast cancer risk

Breast cancer - Tamoxifen: risk of reduced therapeutic response in patients who are poor CYP2D6 metabolisers or use medicines inhibiting CYP2D6

CETP inhibitors: safety and efficacy of Anacetrapib in patients with coronary heart disease

Zoledronic acid added to standard adjuvant therapy does not show disease free survival advantage compared to standard therapy alone

Aromatase inhibitors appear to increase the risk of cardiac events among women with breast cancer

SAGhE study: increased risk of death in patients treated with recombinant human growth hormone during childhood

DASISION study: results from the 18-month follow up comparing Dasatinib to Imatinib in first-line treatment of adults with Ph+ chronic phase chronic myeloid leukemia

Apixaban in acute coronary syndrome: APPRAISE-2 trial discontinued

Phase 2 interim data have shown high objective response rate for patients treated with Elotuzumab plus Lenalidomide and low-dose Dexamethasone

Krystexxa for the treatment of chronic gout in adult patients refractory to conventional therapy

Oral Laquinimod for multiple sclerosis: initial results from ALLEGRO study

Intravenous Dexamethasone may reduce risk of dying from bacterial meningitis

Alzheimer’s disease: Vitamin B12 may reduce risk

Severe headache: Acetylsalicylic acid given intravenously is safe and effective

Amyotrophic lateral sclerosis: Lithium shows no benefit

Provenge, cellular immunotherapy for advanced prostate carcinoma

FDA: increased risk of death with Tygacil compared to other antibiotics

EMA: the use of Modafinil should be restricted to the treatment of narcolepsy

Chronic lymphocytic leukaemia: NICE recommends MabThera for NHS use

Moderate-to-severe Alzheimer's disease: higher dose Aricept 23 mg approved by FDA

Bevacizumab-based therapy extends survival beyond fourteen months in patients with advanced non-small cell lung cancer

PLX4032: preliminary phase 2 data in metastatic melanoma

Chronic obstructive pulmonary disease: beta-blockers may be associated with benefits

Paroxysmal atrial fibrillation: prescription Omega-3 no better than placebo

ASCEND-HF trial: Nesiritide is safe, but shows no significant benefit on symptoms or mortality in acutely decompensated heart failure

Higher dose of Clopidogrel no better than standard dose for high risk patients with drug-coated stents

Erbitux does not add benefit to the NORDIC FLOX regimen in treatment of metastatic colorectal cancer

PARP inhibitors: Iniparib improves overall survival in metastatic triple-negative breast carcinoma

Glucosamine, Chondroitin do not reduce joint pain or have an impact on narrowing of joint space in osteoarthritis of the hip or knee

Vectibix fails to add overall survival benefit in recurrent, metastatic head and neck squamous cell carcinoma

Votrient shows promise in relapsed, refractory urothelial carcinoma

Prolia as a treatment option for certain postmenopausal women who are at increased risk of primary and secondary osteoporotic fractures if other treatments are unsuitable

Revolade for the treatment of idiopathic thrombocytopenic purpura is not recommended

Increased risk of suicide with Vigabatrin, Levetiracetam and Topiramate

Votrient in the treatment of advanced renal cell carcinoma and ovarian carcinoma

Diabetes mellitus type 2: restrict the use of Rosiglitazone

Atrial fibrillation: Rivaroxaban comparable to Warfarin in preventing stroke and other complications

Belimumab: safety findings

Pagine successive [1] 2 3 4

Xagena Salute

Xagena Network

News

Database

Search

FarmaExplorer

MediExplorer

Video

MedCommunity

Loading

Patologie

© XAGENA 2010 - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati